glp 1 suicidal ideation Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study GLP-1 therapy may reduce suicidal

Petrelintide, a long-acting amylin analog, is being tested in Phase II trials and may offer improved tolerability and sustained weight loss.

Amgens MariTide leads the GLP-1 obesity therapy market in 2025 with innovative design, Phase-3 trials, and strong potential for effective weight loss.

Bariatric Fusions bariatric multivitamins and supportive supplements are formulated by a team of bariatric practitioners to support nutrient absorption for those who have undergone ASMBS-endorsed procedures, including duodenal switch, SIPS, SADI-S, sleeve gastrectomy, gastric bypass surgery, lap band, and intra-gastric balloon

Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective for body weight reduction, there remains a critical unmet need for complementary strategies that drive selective fat loss and sustain long-term weight reduction